强直与簇状脊髓电刺激波形治疗慢性难治性疼痛:随机对照试验研究方案
这是一项正在进行的多中心随机对照交叉试验,旨在为簇状刺激获得美国食品药品监督管理局(FDA)批准提供依据。受试者随机接受先12周强直后12周簇状刺激,或相反顺序,主要终点为每个12周刺激期末平均总体视觉模拟量表(VAS)评分的受试者内差异所体现的簇状刺激相对强直刺激的非劣效性。
要点
- 簇状刺激在小型非对照研究中显示前景,但尚未在美国获批使用。
- 随机交叉设计比较12周强直与12周簇状刺激,主要终点为VAS评分的非劣效性。
- 24周后受试者选择偏好疗法,每6个月随访至2年,收集不良事件。
核心结论
- 该试验是迄今为止规模最大的簇状刺激对照试验,预期将提供关于簇状刺激安全性和有效性的重要信息。
研究设计与样本
- 多中心、随机、对照、交叉试验,受试者为当前已获批神经刺激装置的候选者,经筛选入组。
- 符合条件并接受永久植入的受试者随机接受:先12周强直刺激后12周簇状刺激,或先12周簇状刺激后12周强直刺激。
- 评估在第6、12、18、24周进行;24周后受试者选择偏好疗法,每6个月评估一次,最长至2年。
主要发现
- 所有患者的装置导线插入部位依据成功的强直刺激试验确定。
- 评估包括使用视觉模拟量表(VAS)记录总体、躯干和肢体疼痛的疼痛日记,以及贝克抑郁量表、疼痛灾难化量表、Oswestry功能障碍指数、感觉异常、满意度和疗法偏好。
- 主要终点为簇状刺激相对强直刺激的非劣效性,通过每个12周刺激期末平均总体VAS评分的受试者内差异衡量。
- 研究全程收集报告的不良事件。
关键数值与推荐
- 排除标准包括:未通过强直刺激试验评估、有明显抑郁症状、或因未完成7天疼痛日记而显示缺乏研究程序依从性。
- 主要终点为每个12周刺激期末平均总体VAS评分的受试者内差异所体现的簇状刺激相对强直刺激的非劣效性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Burst stimulation is a novel form of neurostimulation for the treatment of chronic pain which has demonstrated promise in small uncontrolled studies, but has not yet gained approval for use in the U.S. We report the study methods for an ongoing multicenter, randomized, controlled, cross-over study designed to gain United States Food and Drug Administration (FDA) approval for burst stimulation. METHODS: Participants who are candidates for a currently approved neurostimulation device were enrolled and screened. Participants who fail a tonic trial evaluation, have significant depressive symptoms, or evidence lack of compliance with study procedures by failing to complete 7 days of a Pain Diary are excluded. Participants receiving a permanent implant are randomized to receive: (1) 12 weeks of tonic followed by 12 weeks of burst stimulation or (2) 12 weeks of burst stimulation followed by 12 weeks of tonic stimulation. Assessments occur at 6, 12, 18, and 24 weeks. After 24 weeks, participants choose their preferred therapy and are assessed every 6 months for up to 2 years. All patients had the device leads inserted at the site of a successful tonic stimulation trial. Assessments include: a Pain Diary using a Visual Analog Scale (VAS) for overall, trunk, and limb pain, the Beck Depression Inventory, the Pain Catastrophizing Scale, the Oswestry Disability Index, paresthesia, satisfaction, and therapy preference. Reported adverse events are collected throughout the study. The primary endpoint is the noninferiority of burst stimulation compared to tonic measured by the within-subject difference in the mean overall VAS score at the end of each 12-week stimulation period. DISCUSSION: This trial represents the largest controlled trial of burst stimulation to date, and is expected to yield important information regarding the safety and efficacy of burst stimulation. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02011893 . Registered on 10 December 2013.
引用
- Slavin KV, North RB, Deer TR, et al. Tonic and burst spinal cord stimulation waveforms for the treatment of chronic, intractable pain: study protocol for a randomized controlled trial. Trials. 2016. PMID: 27906080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。